Curatio pulmonis cancer in cellula parva non-
Curatio cancri pulmonis maxime utitur chirurgia, radiotherapia et chemotherapy, et chirurgia est adhuc validissima methodus curandi cancri pulmonis in primis et mediis gradibus. Tamen, pro cancro centrali pulmonis, ob peculiarem locum laesionem, rationes chirurgicae traditionales difficiles sunt ad efficiendum, et aegroti saepe casu remedii amittunt.
Central lung cancer refers to lung cancer that occurs in the bronchi, lobular bronchus, and lung bronchus, with squamous carcinoma and undifferentiated carcinoma mostly. Surgery is rarely used for central pulmonis cancer,. This is because central lung cancer is located near the hilum. It is difficult to remove, and the surgical effect is not ideal. It is easy to induce bone metastasis . Therefore, in the past, clinicians often were helpless when treating central lung cancer.
Etiam cum emendatio technologiae chirurgiae pulmonis, usus pneumonectomy intrapericardialis, indicia chirurgica quodammodo dilatavit et rate resectionem auxit. Tamen, secundum data clinica, in curatione cancri pulmonis centralis, efficacia resectionis chirurgicae non bene aestimatur, praesertim aegris cum cancro pulmonis progresso, resectio chirurgica plerumque dissolutus est. Curatio cancri centralis pulmonis, etiam si thoracotomia est, maxime exploratio chirurgiae et chirurgiae palliativae est. Seniores aegros cor malum habent et difficile est chirurgicam anaesthesiam transire.
The birth of EDGE has completely changed the dilemma of the treatment of central lung cancer. This technology can effectively remove tuberculum lesions in vitro and remove the central lung cancer lesions in vitro. The treatment effect can be comparable to surgical operations, but there is no surgical operation for patients. Caused by trauma and side effects.
Experts from the Global Oncologist Network introduced that EDGE, which was launched in 2014, is by far the most advanced in-vitro non-invasive tumor removal technology. It can remove tumor lesions in the body without any damage to the patient’s body and immune system. This technique is particularly suitable for patients with tumors that were previously inoperable, such as lung cancer, brain tumors, spine tumors, caput et collum tumors, pancreatic cancer, prostate cancer and other diseases.
Male, 53 years old, suffering from cellula parva non-pulmonis cancer with multiple metastatic brain tumors. In early June 2014, he went to Henry Ford Hospital for EDGE non-invasive radiosurgery. EDGE treatment 3 times, continuous daily treatment, once a day, each time takes about 12 minutes. The first time after operation, the patient’s headache was obviously relieved, and the patient is generally in good condition so far. During the follow-up in early September, the local hospital in Taipei underwent MRI examination: 0.9 and 4 cm3 tumores in cerebro almost disappeared, and 6.5 cm3 tumors in the lungs decreased by more than 98%.
ORA systematis radiosurgiae (ACGE systematis tumoris radiosurgiae curationis) a societate American Varian evoluta est et ab US FDA die 23 mensis Ianuarii anno MMXIII probata est. ACIES longe efficacissima tumore technologiae remotionis non incursivae. Unico FDA Calypso® GPS utitur ad systema corporis et radiorum superficiei systematis vigilantia die 2013 iulii 21 probata, ut monitorem dynamice claudat et in reali tempore in magna frequentia usque ad 2014 millium secundorum. In curatione tumor "effugit", cum nova generatione IGRT et aliarum imaginum technologiarum ductu componitur, et singulari intensitate collimatoris HD-MLC usque ad 10MU/min utitur, ut tumorem textus cum nulla fere accuratione residua removeat.
Primum ORA systematis mundi in Civitatibus Foederatis Americae Systema Sanitatis Henrici Ford (HFHS, Americana Henry Ford Medical Group) mense Septembri 2013 consedit, et primam operationem suam mense Martio MMXIV incepit.
EDGE has an excellent therapeutic effect on solid tumors such as head tumors, lung cancer including breast cancer, spine tumors, iecoris cancer and other tumors that are difficult to perform in conventional surgery. The entire treatment process is non-invasive, no anesthesia, no hospitalization, each treatment time is 8-20 minutes, once a day, up to 5 times, continuous daily treatment. EDGE treatment has almost no side effects, almost no damage to important organs, and almost no effect on the body’s anti-cancer immune system.
Utilitates ACIES radiosurgiae non incursio surgery
Ø Brevis curatio tempus: 8-20 minuta singulis temporibus;
Ø Curatio temporum: summa 1-5 temporum, continua curatio, semel in die;
Ø Maximum efficientiam: multiplex tumor foci simul purgari potest;
Ø Real-time vestigatio tumoris effugii et amotionis: Track et cohibere tumorem "effugere" cum altissima frequentia 10 milliseconds et removere;
Ø Bonus effectus remotionis: alta virtus, alta subtilitas et alta accuratio, perfecta remotio tumoris textus cum fere nulla residuo;
Ø Nulla fere pernicies organis momentis: paene nulla detrimenta fibris et organis momentis;
Ø Anti-cancrus corporis immunis ratio damnum parum valet: fere nullum effectum habet in propria systema immune;
Ø Commodum: non anesthesia et non hospitalization;
Ø Parte effectus: nulla fere parte effectus sunt.
